Lupus Therapeutic Market Set To Witness High Growth Due To Rising Lupus Disease Prevalence

Lupus Therapeutic Market

The lupus therapeutic market contains drugs that are used for the treatment of systemic lupus erythematosus (SLE), commonly known as lupus. Lupus is an autoimmune disease where the immune system of the body mistakenly attacks healthy cells and tissues. It can potentially damage any part of the body like joints, skin, kidneys, blood cells, brain, heart and lungs. Biologic therapies, immunosuppressants and corticosteroids are some of the key drug classes used for managing lupus symptoms and minimizing damage caused by inflammation. The need for effective treatment of lupus has been rising due to increasing cases of the disease globally. It is estimated that about 1.5 million Americans and at least 5 million people worldwide suffer from lupus.

The global lupus therapeutic market is estimated to be valued at US$ 3497 Mn in 2024 and is expected to exhibit a CAGR of 5.6% over the forecast period 2024 to 2031.

Key Takeaways
Key players operating in the Lupus Therapeutic Market Size are Pfizer Inc., Abbott Laboratories, AstraZeneca Plc., Novartis AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Sanofi S.A.

Key opportunities in the market include new product development and increasing awareness about lupus. For instance, there is an ongoing focus on developing novel oral therapies that can replace injectables for improved patient convenience. Further, expanding healthcare access in developing nations will help in providing treatment to a larger patient pool.

Globally, companies are focusing on geographic expansion and opening manufacturing facilities across markets like Asia Pacific and Latin America. This helps them address the rising demand and gain immediate market share. Availability of generic drugs at lower costs also favorably impacts the industry in lower income countries.

Market drivers: The increasing prevalence of lupus across all age groups is a key factor driving the demand for effective treatment options. According to estimates, around 1.5 million Americans suffer from lupus currently and the number is steadily rising. Further, the market is witnessing favourable reimbursement policies for branded lupus drugs in developed nations.

Market restraints: High developmental costs of novel therapies and long regulatory approval timelines are some challenges faced by players. The unpredictable nature and complexity of lupus also makes drug development difficult. Further, patent expiries of major drugs result in revenue losses for companies. This continues to restraint market growth to some extent.

Segment Analysis

The Lupus Therapeutic Market is dominanted by systemic lupus erythematosus sub segment. This is because SLE represents around 90% of total lupus cases. SLE can affect multiple organ systems like kidneys, brain, heart lungs and joints. There is no permanent cure for SLE and it requires lifelong treatment to control symptoms and prevent organ damage.

Global Analysis

The North American region is projected to be the fastest growing as well as dominating region in the Lupus Therapeutic Market during the forecast period. This is because of continuously rising prevalence of lupus, growing awareness initiatives by government and non-profit organizations and new product launches in the region. The increasing research and development funding by both public and private organizations for lupus therapeutics is also expected to drive the market growth in North America.

Get more insights, On Lupus Therapeutic Market